Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biejia-Ruangan Compound for HCC Recurrence After Radical Treatment
NCT06923176Phase 4Not yet recruiting
- Start
- Apr 2025
- Primary completion
- Apr 2031
- Modality
- HM (Herbal Medicine)
01
Overview
Phase 4, open-label trial of Fufang Biejia Ruangan in hepatocellular carcinoma (HCC) (2 arms). Primary endpoint: Recurrence-free survival at 96 weeks. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
Fufang Biejia Ruangan
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06923176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06923176.